Base editing gene therapy is rewriting the story for sickle cell patients, turning suffering into strength. Branden Baptiste experienced his first sickle cell crisis at just 2 years old ...

Improved Prime Editing System Makes Gene-Sized Edits in Human Cells at Therapeutic Levels June 10, 2024 — Scientists have improved a gene-editing technology that is now capable of inserting or ...

Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.

SAN DIEGO — New and ex­per­i­men­tal gene ther­a­pies made with blood stem cells re­ly on the same gru­el­ing, decades-old meth­ods for a process called con­di­tion­ing … ...

applied exclusively SMs as cell conversion inducers, without the use of vector-based exogenous gene expression approaches; c) used non-neural somatic cells as a source for neural transdifferentiation; ...

40% HSC editing using Cas12a and proprietary lipid nanoparticles; HbF expression reached 20% in human red blood cells within one ... Editas achieved high-efficiency gene editing in non-human ...

Two prominent gene-editing startups, Chroma Medicine and Nvelop Therapeutics, said Wednesday they will merge, forming a new company called nChroma Bio. The merger will combine molecular machines ...

the Massachusetts-based firm is shifting focus to developing in vivo CRISPR-edited medicines and is shelving its lead gene-editing program for sickle cell disease (SCD). Editas (EDIT) said it is ...